{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:44:19Z","timestamp":1772804659930,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The purpose of this study is to review the literature on the risk of malignancy in patients with inflammatory eye disease (IED) treated with systemic immunosuppressive (IS) therapy. Relevant databases in transplant medicine, autoimmune diseases and literature regarding uveitis and scleritis were reviewed. Literature with regards systemic IS therapy in transplant recipients and patients with autoimmune diseases revealed a significant increase in malignancies, especially non-melanocytic skin cancers and lymphomas. Studies of patients with IED were limited in number and scope, with no studies adequately evaluating the incidence of malignancy in these patients. Difficulties associated with the evaluation of the risk of malignancy associated with IS therapy in patients with IED include the heterogeneity of the disease and treatment regimens as well as the low frequency of IED, its variable severity and the lack of adequate long-term follow-up studies. Systemic IS therapy is an important therapeutic option in the treatment of patients with severe IED. A well-designed, comprehensive, multi-centre long-term follow-up study is required to evaluate the risk of malignancy in patients with specific IED diseases treated with defined systemic IS therapy. Until such evidence is available, we recommend the adoption of preventative strategies to help minimise the risk of malignancy in such patients.<\/jats:p>","DOI":"10.1186\/1869-5760-3-48","type":"journal-article","created":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T14:05:22Z","timestamp":1370009122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?"],"prefix":"10.1186","volume":"3","author":[{"given":"William B","family":"Yates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,31]]},"reference":[{"key":"50_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00002018-200023020-00002","volume":"23","author":"I Penn","year":"2000","unstructured":"Penn I: Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000, 23: 101\u2013113. 10.2165\/00002018-200023020-00002","journal-title":"Drug Saf"},{"key":"50_CR2","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMra022137","volume":"348","author":"S Euvrard","year":"2003","unstructured":"Euvrard S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. N Engl J Med 2003, 348: 1681\u20131691. 10.1056\/NEJMra022137","journal-title":"N Engl J Med"},{"key":"50_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.12659\/AOT.881859","volume":"16","author":"EBM Watorek","year":"2011","unstructured":"Watorek EBM, Smolska D, Patrzalek D, Klinger M: Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant 2011, 16: 14\u201318.","journal-title":"Ann Transplant"},{"key":"50_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1258\/ijsa.2009.009486","volume":"21","author":"B Kiely","year":"2010","unstructured":"Kiely B, O\u2019Flaherty J, Surah S, Kieran J, O\u2019Donnell D, Bergin C, Mulcahy F: HIV-related malignancies pre- and post-highly active antiretroviral therapy: experiences in an inner city tertiary referral centre. Int J STD AIDS 2010, 21: 332\u2013336. 10.1258\/ijsa.2009.009486","journal-title":"Int J STD AIDS"},{"key":"50_CR5","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1002\/cncr.25311","volume":"116","author":"J Reekie","year":"2010","unstructured":"Reekie J, Kosa C, Engsig F, Monforte A, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A: Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010, 116: 5306\u20135315. 10.1002\/cncr.25311","journal-title":"Cancer"},{"key":"50_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.critrevonc.2005.03.013","volume":"56","author":"G Ippoliti","year":"2005","unstructured":"Ippoliti G, Rinaldi M, Pellegrini C, Vigan M: Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol 2005, 56: 101\u2013113. 10.1016\/j.critrevonc.2005.03.013","journal-title":"Crit Rev Oncol Hematol"},{"key":"50_CR7","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3899\/jrheum.100041","volume":"37","author":"M Krathen","year":"2010","unstructured":"Krathen M, Gottlieb A, Mease P: Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol 2010, 37: 2205\u20132215. 10.3899\/jrheum.100041","journal-title":"J Rheumatol"},{"key":"50_CR8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/bmj.320.7234.555","volume":"320","author":"PJ McCluskey","year":"2000","unstructured":"McCluskey PJ, Towle HM, Lightman S: Management of chronic uveitis. BMJ 2000, 320: 555\u2013558. 10.1136\/bmj.320.7234.555","journal-title":"BMJ"},{"key":"50_CR9","first-page":"527","volume":"84","author":"S Foster","year":"1986","unstructured":"Foster S: Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986, 84: 527\u2013663.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"50_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/bjo.57.9.706","volume":"57","author":"MI Abdalla","year":"1973","unstructured":"Abdalla MI, Bahgat N: Long-lasting remission of Behcet's disease after chlorambucil therapy. BJO 1973, 57: 706\u2013711. 10.1136\/bjo.57.9.706","journal-title":"BJO"},{"key":"50_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0161-6420(80)35272-X","volume":"87","author":"S Foster","year":"1980","unstructured":"Foster S: Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology 1980, 87: 140\u2013150.","journal-title":"Ophthalmology"},{"key":"50_CR12","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/00007890-199806150-00007","volume":"65","author":"TH Mathew","year":"1998","unstructured":"Mathew TH, Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Transplantation 1998, 65: 1450\u20131454. 10.1097\/00007890-199806150-00007","journal-title":"Transplantation"},{"key":"50_CR13","first-page":"876","volume":"28","author":"I Penn","year":"1996","unstructured":"Penn I: Cancers in cyclosporine-treated vs azathioprine-treated patients. Transplant Proc 1996, 28: 876\u2013878.","journal-title":"Transplant Proc"},{"key":"50_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1053\/jlts.2001.23356","volume":"7","author":"R Wiesner","year":"2001","unstructured":"Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R, Wang W: A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001, 7: 442\u2013450. 10.1053\/jlts.2001.23356","journal-title":"Liver Transpl"},{"key":"50_CR15","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/S0140-6736(71)90602-7","volume":"298","author":"B Walder","year":"1971","unstructured":"Walder B, Robertson M, Jeremy D: Skin cancer and immunosuppression. Lancet 1971, 298: 1282\u20131283. 10.1016\/S0140-6736(71)90602-7","journal-title":"Lancet"},{"key":"50_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00007890-198701000-00008","volume":"43","author":"I Penn","year":"1987","unstructured":"Penn I: Cancers following cyclosporine therapy. Transplantation 1987, 43: 32\u201335. 10.1097\/00007890-198701000-00008","journal-title":"Transplantation"},{"key":"50_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0041-1345(96)00153-4","volume":"29","author":"C Hiesse","year":"1997","unstructured":"Hiesse C, Rieu P, Kriaa F, Larue JR, Goupy C, Neyrat N, Charpentier B: Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997, 29: 831\u2013833. 10.1016\/S0041-1345(96)00153-4","journal-title":"Transplant Proc"},{"key":"50_CR18","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1136\/bmj.2.6203.1461","volume":"2","author":"L Kinlen","year":"1979","unstructured":"Kinlen L, Sheil A, Peto J, Doll R: Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979, 2: 1461\u20131466. 10.1136\/bmj.2.6203.1461","journal-title":"BMJ"},{"key":"50_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0011-3840(81)80011-1","volume":"18","author":"I Penn","year":"1981","unstructured":"Penn I: The price of immunotherapy. Curr Probl Surg 1981, 18: 681\u2013751. 10.1016\/S0011-3840(81)80011-1","journal-title":"Curr Probl Surg"},{"key":"50_CR20","first-page":"603","volume":"162","author":"I Penn","year":"1986","unstructured":"Penn I: Cancer is a complication of severe immunosuppression. Surg Gynecol Obstet 1986, 162: 603\u2013610.","journal-title":"Surg Gynecol Obstet"},{"key":"50_CR21","first-page":"149","volume":"1","author":"I Penn","year":"1987","unstructured":"Penn I: Neoplastic consequences of transplantation and chemotherapy. Cancer detection and prevention Supplement: official publication of the International Society for Preventive Oncology, Inc. 1987, 1: 149\u2013157.","journal-title":"Cancer detection and prevention Supplement: official publication of the International Society for Preventive Oncology, Inc"},{"key":"50_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/ard.42.4.368","volume":"42","author":"J Baltus","year":"1983","unstructured":"Baltus J, Boersma J, Hartman A, Vandenbroucke J: The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 1983, 42: 368\u2013373. 10.1136\/ard.42.4.368","journal-title":"Ann Rheum Dis"},{"key":"50_CR23","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/art.1780380815","volume":"38","author":"CD Radis","year":"1995","unstructured":"Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA Jr, Kwoh CK: Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995, 38: 1120\u20131127. 10.1002\/art.1780380815","journal-title":"Arthritis Rheum"},{"key":"50_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0002-9343(87)90490-6","volume":"83","author":"G Baker","year":"1987","unstructured":"Baker G, Kahl L, Zee B, Stolzer B, Agarwal A, Medsger T Jr: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case\u2013control follow-up study. Am J Med 1987, 83: 1\u20139.","journal-title":"Am J Med"},{"key":"50_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/0002-9343(85)90245-1","volume":"78","author":"L Kinlen","year":"1985","unstructured":"Kinlen L: Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985, 78: 44\u201349.","journal-title":"Am J Med"},{"key":"50_CR26","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/ard.47.12.988","volume":"47","author":"AJ Silman","year":"1988","unstructured":"Silman AJ, Petrie J, Hazleman B, Evans SJ: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988, 47: 988\u2013992. 10.1136\/ard.47.12.988","journal-title":"Ann Rheum Dis"},{"key":"50_CR27","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/art.23716","volume":"59","author":"R Buchbinder","year":"2008","unstructured":"Buchbinder R, Barber M, Heuzenroeder L, Wluka A, Giles G, Hall S, Harkness A, Lewis D, Littlejohn G, Miller MH, Ryan PF, Jolley D: Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res 2008, 59: 794\u2013799. 10.1002\/art.23716","journal-title":"Arthritis Care Res"},{"key":"50_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","volume":"120","author":"CF Paul","year":"2003","unstructured":"Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L: Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Investig Dermatol 2003, 120: 211\u2013216. 10.1046\/j.1523-1747.2003.12040.x","journal-title":"J Investig Dermatol"},{"key":"50_CR29","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"E Keystone","year":"2004","unstructured":"Keystone E, Kavanaugh A, Sharp J, Tannenbaum H, Hua Y, Teoh L, Fischkoff SA, Chartash EK: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50: 1400\u20131411. 10.1002\/art.20217","journal-title":"Arthritis Rheum"},{"key":"50_CR30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/art.34348","volume":"64","author":"T Beukelman","year":"2012","unstructured":"Beukelman T, Haynes K, Curtis J, Xie F, Chen L, Bemrich-Stolz C, Delzell E, Saag KG, Solomon DH, Lewis JD: Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012, 64: 1263\u20131271. 10.1002\/art.34348","journal-title":"Arthritis Rheum"},{"key":"50_CR31","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.ophtha.2008.08.002","volume":"115","author":"JE Thorne","year":"2008","unstructured":"Thorne JE, Woreta FA, Jabs DA, Anhalt GJ: Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology 2008, 115: 2146\u20132152. e1 10.1016\/j.ophtha.2008.08.002","journal-title":"Ophthalmology"},{"key":"50_CR32","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S0161-6420(95)30835-4","volume":"102","author":"L Lane","year":"1995","unstructured":"Lane L, Tamesis R, Rodriguez A, Christen W, Akova Y, Messmer E, Pedroza-Seres M, Barney N, Foster CS: Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Ophthalmology 1995, 102: 1530\u20131535.","journal-title":"Ophthalmology"},{"key":"50_CR33","first-page":"421","volume-title":"Increased risk of malignancy in patients with uveitis treated with systemic immunosuppressive therapy","author":"NL Murray","year":"1994","unstructured":"Murray NL, McCluskey PJ, Wakefield D: Increased risk of malignancy in patients with uveitis treated with systemic immunosuppressive therapy. Elsevier, New York; 1994:421\u2013424."},{"key":"50_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1432-2277.2006.00330.x","volume":"19","author":"M Kauffman","year":"2006","unstructured":"Kauffman M, Cherikh W, McBride M, Cheng Y, Hanto D: Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006, 19: 607\u2013620. 10.1111\/j.1432-2277.2006.00330.x","journal-title":"Transpl Int"},{"key":"50_CR35","first-page":"885","volume":"20","author":"I Penn","year":"1988","unstructured":"Penn I, Brunson ME: Cancers after cyclosporine therapy. Transplant Proc 1988, 20: 885\u2013892.","journal-title":"Transplant Proc"},{"key":"50_CR36","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/00007890-199003000-00006","volume":"49","author":"M Hartevelt","year":"1990","unstructured":"Hartevelt M, Bavinck J, Kootte A, Vermeer B, Vandenbroucke J: Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990, 49: 506\u2013509. 10.1097\/00007890-199003000-00006","journal-title":"Transplantation"},{"key":"50_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nrneph.2010.102","volume":"6","author":"I Rama","year":"2010","unstructured":"Rama I, Grinyo JM: Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol 2010, 6: 511\u2013519. 10.1038\/nrneph.2010.102","journal-title":"Nat Rev Nephrol"},{"key":"50_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1751-1097.1989.tb04078.x","volume":"49","author":"G Kelly","year":"1989","unstructured":"Kelly G, Meikle W, Moore D: Enhancement of UV-induced skin carcinogenesis by azathioprine: role of photochemical sensitisation. Photochem Photobiol 1989, 49: 59\u201365. 10.1111\/j.1751-1097.1989.tb04078.x","journal-title":"Photochem Photobiol"},{"issue":"5","key":"50_CR39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/00007890-199603150-00008","volume":"61","author":"J Bavinck","year":"1996","unstructured":"Bavinck J, Hardie D, Green A, Cutmore S, MacNaught A, O\u2019Sullivan B, Siskind V, Van Der Woude FJ, Hardie IR: The risk of skin cancer in renal transplant recipients in Queensland. Australia. A follow-up study. Transplantation 1996,61(5):715\u201321. 10.1097\/00007890-199603150-00008","journal-title":"Transplantation"},{"key":"50_CR40","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/sj.onc.1201339","volume":"15","author":"JM McGregor","year":"1997","unstructured":"McGregor JM, Berkhout RJM, Rozycka M, Schegget J, Bouwes Bavinck JN, Brooks L, Crook T: p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomarivus status. Oncogene 1997, 15: 1737\u20131740. 10.1038\/sj.onc.1201339","journal-title":"Oncogene"},{"key":"50_CR41","first-page":"513","volume":"143","author":"B Lindel\u00f6f","year":"2000","unstructured":"Lindel\u00f6f B, Sigurgeirsson B, G\u00e4bel H, Stern RS: Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000, 143: 513\u2013519.","journal-title":"Br J Dermatol"},{"key":"50_CR42","first-page":"1705","volume":"26","author":"P Asten","year":"1999","unstructured":"Asten P, Barrett J, Symmons D: Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999, 26: 1705\u20131714.","journal-title":"J Rheumatol"},{"key":"50_CR43","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","volume":"32","author":"L Mellemkj\u00e6r","year":"1996","unstructured":"Mellemkj\u00e6r L, Linet MS, Gridley G, Frisch M, M\u00f8ller H, Olsen JH: Rheumatoid arthritis and cancer risk. Eur J Cancer 1996, 32: 1753\u20131757. 10.1016\/0959-8049(96)00210-9","journal-title":"Eur J Cancer"},{"issue":"1","key":"50_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/rheumatology\/kes189","volume":"52","author":"C Turesson","year":"2013","unstructured":"Turesson C, Matteson EL: Malignancy as a comorbidity in rheumatic diseases. Rheumatology (Oxford) 2013,52(1):5\u201314. 10.1093\/rheumatology\/kes189","journal-title":"Rheumatology (Oxford)"},{"key":"50_CR45","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","volume":"31","author":"H Isomaki","year":"1978","unstructured":"Isomaki H, Hakulinen T, Joutsenlahti U: Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978, 31: 691\u2013696. 10.1016\/0021-9681(78)90071-1","journal-title":"J Chronic Dis"},{"key":"50_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0049-0172(99)80026-2","volume":"29","author":"P Beauparlant","year":"1999","unstructured":"Beauparlant P, Papp K, Haraoui B: The incidence of cancer associated with the treatmentof rheumatoid arthritis. Semin Arthritis Rheum 1999, 29: 148\u2013158. 10.1016\/S0049-0172(99)80026-2","journal-title":"Semin Arthritis Rheum"},{"key":"50_CR47","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"LBA van de Putte","year":"2004","unstructured":"van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, Settas L, Bijlsma J, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63: 508\u2013516. 10.1136\/ard.2003.013052","journal-title":"Ann Rheum Dis"},{"key":"50_CR48","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006, 295: 2275\u20132285. 10.1001\/jama.295.19.2275","journal-title":"JAMA"},{"key":"50_CR49","doi-asserted-by":"publisher","first-page":"b2480","DOI":"10.1136\/bmj.b2480","volume":"339","author":"J Kempen","year":"2009","unstructured":"Kempen J, Ebenezer D, Dun J, Foster P, Gangaputra P, Hanish A, Helzlsouer KJ, Jabs DA, Ka\u00e7maz RO, Levy-Clarke GA, Liesegang TL, Newcomb CW, Nussenblatt RB, Pujari SS, Rosenbaum JT, Suhler EB, Thorne JE: Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009, 339: b2480. 10.1136\/bmj.b2480","journal-title":"BMJ"},{"key":"50_CR50","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/0003-4975(95)00120-4","volume":"60","author":"SM Pham","year":"1995","unstructured":"Pham SM, Kormos RL, Landreneau RJ, Kawai A, Gonzalez-Cancel I, Hardesty RL, Hattler BG, Griffith BP: Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 1995, 60: 1623\u20131626. 10.1016\/0003-4975(95)00120-4","journal-title":"Ann Thorac Surg"},{"key":"50_CR51","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1600-6143.2011.03515.x","volume":"11","author":"M Crespo-Leiro","year":"2011","unstructured":"Crespo-Leiro M, Villa-Arranz A, Manito-Lorite N, Paniagua-Martin M, R\u00e1bago G, Almenar-Bonet L, Alonso-Pulp\u00f3n L, Mirabet-P\u00e9rez S, Diaz-Molina B, Gonz\u00e1lez-Vilchez F, Ariz\u00f3n de Prado JM, Romero-Rodriguez N, Delgado-Jimenez J, Roig E, Blasco-Peir\u00f3 T, Pascual-Figal D, De la Fuente GL, Mu\u00f1iz J: Lung cancer after heart transplantation: results from a large multicenter registry. Am J Transplant 2011, 11: 1035\u20131040. 10.1111\/j.1600-6143.2011.03515.x","journal-title":"Am J Transplant"},{"key":"50_CR52","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1568-9972(03)00102-2","volume":"3","author":"Y Masaki","year":"2004","unstructured":"Masaki Y, Sugai S: Lymphoproliferative disorders in Sjogren's syndrome. Autoimmun Rev 2004, 3: 175\u2013182. 10.1016\/S1568-9972(03)00102-2","journal-title":"Autoimmun Rev"},{"key":"50_CR53","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1365-4362.1989.tb02534.x","volume":"28","author":"D Hogan","year":"1989","unstructured":"Hogan D, To T, Gran L, Wong D, Lane P: Risk factors for basal cell carcinoma. Int J Dermatol 1989, 28: 591\u2013594. 10.1111\/j.1365-4362.1989.tb02534.x","journal-title":"Int J Dermatol"},{"key":"50_CR54","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/rheumatology\/35.8.738","volume":"35","author":"M Jones","year":"1996","unstructured":"Jones M, Symmons D, Finn J, Wolfe F: Does exposure to immunosuppresive therapy increase the 10 year maligancy and mortality risks in rheumatoid arthritis? A matched cohort study. Rheumatology (Oxford) 1996, 35: 738\u2013745. 10.1093\/rheumatology\/35.8.738","journal-title":"Rheumatology (Oxford)"},{"key":"50_CR55","first-page":"116","volume":"158","author":"I Flytstr\u00f6m","year":"2008","unstructured":"Flytstr\u00f6m I, Stenberg B, Svensson \u00c5, Bergbrant IM: Methotrexate vs. cyclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008, 158: 116\u2013121.","journal-title":"Br J Dermatol"},{"key":"50_CR56","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1136\/ard.2008.102103","volume":"68","author":"G Burmester","year":"2009","unstructured":"Burmester G, Mease P, Dijkmans B, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL: Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009, 68: 1863\u20131869. 10.1136\/ard.2008.102103","journal-title":"Ann Rheum Dis"},{"key":"50_CR57","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","volume":"134","author":"R Buchbinder","year":"2001","unstructured":"Buchbinder R, Forbes A, Hall S, Dennett X, Giles G: Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001, 134: 1087\u20131095. 10.7326\/0003-4819-134-12-200106190-00008","journal-title":"Ann Intern Med"},{"key":"50_CR58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0190-9622(99)70185-4","volume":"40","author":"P Jensen","year":"1999","unstructured":"Jensen P, Hansen S, M\u00f8ller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P, Simonsen S: Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999, 40: 177\u2013186. 10.1016\/S0190-9622(99)70185-4","journal-title":"J Am Acad Dermatol"},{"key":"50_CR59","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0161-6420(99)90156-2","volume":"106","author":"L Myra","year":"1999","unstructured":"Myra L, Sloper C, Powell RJ, Dusa HS: Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999, 106: 723\u2013728. 10.1016\/S0161-6420(99)90156-2","journal-title":"Ophthalmology"},{"key":"50_CR60","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT: A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005, 123: 903\u2013912. 10.1001\/archopht.123.7.903","journal-title":"Arch Ophthalmol"},{"key":"50_CR61","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/ICU.0b013e3282f03d42","volume":"18","author":"F Imrie","year":"2007","unstructured":"Imrie F, Dick A: Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007, 18: 481\u2013486. 10.1097\/ICU.0b013e3282f03d42","journal-title":"Curr Opin Ophthalmol"},{"key":"50_CR62","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S0140-6736(97)80015-3","volume":"349","author":"MT Glover","year":"1997","unstructured":"Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM: Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997, 349: 398.","journal-title":"Lancet"},{"key":"50_CR63","first-page":"217","volume":"5","author":"K Houston","year":"1978","unstructured":"Houston K, O\u2019Duffy J, McDuffie F: Behcet's disease associated with a lymphoproliferative disorder, mixed cryoglobulinemia, and an immune complex mediated vasculitis. J Rheumatol 1978, 5: 217\u2013223.","journal-title":"J Rheumatol"},{"key":"50_CR64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s100670170036","volume":"20","author":"M Cengiz","year":"2001","unstructured":"Cengiz M, Altundag M, Zorlu A, G\u00fcll\u00fc I, \u00d6zyar E, Atahan I: Malignancy in Beh\u00e7et's disease: a report of 13 cases and a review of the literature. Clin Rheumatol 2001, 20: 239\u2013244. 10.1007\/s100670170036","journal-title":"Clin Rheumatol"},{"key":"50_CR65","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1136\/thx.52.10.892","volume":"52","author":"N Seersholm","year":"1997","unstructured":"Seersholm N, Vestbo J, Viskum K: Risk of malignant neoplasms in patients with pulmonary sarcoidosis. Thorax 1997, 52: 892\u2013894. 10.1136\/thx.52.10.892","journal-title":"Thorax"},{"issue":"Suppl 3","key":"50_CR66","first-page":"S1","volume":"9","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009,9(Suppl 3):S1-S155.","journal-title":"Am J Transplant"},{"key":"50_CR67","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMoa1204166","volume":"367","author":"S Euvrard","year":"2012","unstructured":"Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GFL, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J: Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012, 367: 329\u2013339. 10.1056\/NEJMoa1204166","journal-title":"N Engl J Med"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1869-5760-3-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:21:25Z","timestamp":1630542085000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/1869-5760-3-48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,31]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1186\/1869-5760-3-48","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,31]]},"assertion":[{"value":"22 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"48"}}